Bionow | News

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment...

Nov 27th 2024

Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targetin...

Apini Secures Major Investment as Part of Slingshot Therapeutics Launch

Nov 21st 2024

Apini, a spinout from The University of Manchester and the first programme launched through newly formed Slingshot Therapeutics Limited (“Slingshot”), is poised to accelerate the develop...

Monument Therapeutics Secures £1M Investment to Advance Schizophrenia Treatment...

Oct 21st 2024

Monument Therapeutics, a leader in precision neuroscience, has announced a significant £1 million equity investment from the Forster Foundation, a charitable organization.

Liverpool to lead new national healthcare research Hub for Advanced Long-acting ...

Oct 16th 2024

A new national research hub, led by the University of Liverpool, will position the UK as a world leader in the emerging global field of long-acting therapeutics (LATs).

BioTryp Therapeutics Raises Pre-Seed Funding to advance its novel biofilm-inhibi...

Sep 20th 2024

Cambridge, UK: BioTryp Therapeutics, an award-winning drug discovery spin-out from the University of Cambridge, has raised £300k in pre-seed funding to advance the development of its novel ...

Precision neuroscience company Monument Therapeutics announces £1.5m funding to...

Apr 22nd 2024

Monument Therapeutics, a precision neuroscience company, today announced new funding of £1.5 million from a combination of equity investment and non-dilutive grant as part of the Innovate U...

Major funding extension to advance revolutionary long-acting therapeutic technol...

Apr 22nd 2024

Unitaid has awarded more than £6M of new funding to a University of Liverpool-led project aiming to improve the long-acting therapeutics available to treat or prevent tuberculosis, malaria ...

Drug Discovery and Advanced Therapeutics Innovation Lab

Feb 15th 2024

The University of Manchester is looking for businesses active in the Drug Discovery and Advanced Therapeutics field to join a sandpit event aimed at fostering academic-industry collaboration...

Aptamer Group signs two substantial new contracts

Jan 25th 2023

Contracts worth over £500,000 with the potential for downstream milestone and royalty/ licensing payments

£1.3M to develop new inhaled drug delivery platforms to treat viral and bacteri...

Mar 8th 2022

The University of Liverpool in partnership with the Liverpool School of Tropical Medicine have joined forces on a £1.3million research project to develop new inhaled drug delivery platforms...

Aptamer Group and WuXi AppTec Research Service Division collaborate to identify ...

Jul 22nd 2021

Aptamer Group Limited, the developer of Optimer™ therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, today annou...

LSTM receives multi million grant to improve product development for Infectious ...

Jul 16th 2020

LSTM has received a grant of £3.3million of the European Regional Development Fund to improve the product development in the formulation of infectious diseases therapeutics.

News